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Reliable measures of antifungal drug susceptibility are needed. We tested the susceptibility of Cryptococcus
neoformans from patients treated with amphotericin B. In vitro susceptibility employed a modified broth
macrodilution method. We demonstrate a strong correlation between the quantitative measures of in vitro
amphotericin B susceptibility and the quantitative response observed in patients.
Physicians have long searched for a laboratory test that
could predict the treatment response in patients with systemic
fungal infections. Unfortunately, despite several decades of
effort, no standard method for testing the susceptibility of
Cryptococcus neoformans to antifungal drugs has been estab-
lished (2, 5). A reproducible method for susceptibility testing
has been proposed, but no interpretive guidelines have been
identified (8–11).
(This work was presented in part at the 6th International
Conference on Cryptococcus and Cryptococcosis, Boston, MA,
June 2005.)
Patients. Data and isolates were from patients in Thailand
(1). Fifteen patients were treated with intravenous amphoter-
icin B (AmB) alone at 0.7 mg/kg of body weight daily for 14
days. The patients’ pretreatment severity of meningitis and
quantitative responses at 14 days were measured by the num-
bers of C. neoformans isolates per milliliter of cerebrospinal
fluid (CSF).
Mycology. C. neoformans isolates recovered from CSF prior
to treatment were stored at 20°C until use. The MICs for
AmB for isolates from the 13 patients alive at day 14 were
determined using the standard CLSI (formerly NCCLS) mi-
crotiter method and employing a broth macrodilution method
modified to count the viable organisms after 48 h of incubation
(9). Susceptibility for each isolate was measured on at least two
separate occasions using a standard inoculum (500 CFU/ml)
and an inoculum that corresponded to the numbers of CFU
per milliliter in the pretreatment CSF (“patient-specific inoc-
ulum”). The inoculum was confirmed by quantitative culture.
Susceptibility was retested if the inoculum was not within 8%
of the target. Following 48 h of incubation, the number of CFU
per milliliter at each concentration was determined. AmB con-
centrations ranged from 0 to 2.0 mg/liter.
Statistical analysis. Local nonparametric regression was
used to estimate the AmB concentration-response curve for
each isolate (3, 4). If the 99% confidence intervals (CIs) for the
response curves for the replicates for a given isolate did not
overlap or if the CI width was greater than 2 log10, the suscep-
tibility test was repeated. For each patient, the concentration
of AmB that produced that patient’s response was estimated by
the point on the in vitro response curve where the in vitro
response matched the patient response. Spearman’s rank cor-
relation was used to evaluate the association between in vitro
response and patient response (6).
Results. The number of CFU per milliliter in the pretreat-
ment CSF ranged from 14,250 to 7,200,000 (4 to 7 log10). For
the 13 patients alive at day 14, the number of CFU per milli-
liter in the CSF ranged from 0 to 7,800 (0 to 4 log10). Figure 1A
shows the AmB concentration-response curve for each isolate.
Each curve at the point where the in vitro response matches
the patient response was indicated (Fig. 1A). The AmB con-
centration producing this response estimates the in vitro equiv-
alent concentration (EC) that predicts the response in patients
treated with AmB for 14 days. The two curves in Fig. 1A
without a diamond are for isolates where the observed patient
responses were lower than the in vitro responses at the highest
concentration tested. Linear extrapolation was used to esti-
mate the AmB EC for these two patients.
The median of the estimated concentrations was 1.5 mg/liter
(95% CI, 1.3 to 1.7). The reproducibility of this estimated EC
was assessed by measuring the susceptibility in the replicate
(data not shown). In the replicates, the median concentration
of AmB that predicts the patient’s response was 1.5 mg/liter
(95% CI, 1.3 to 1.7). Figure 1B shows the association between
the in vitro responses at the AmB EC (1.5 mg/liter) and the
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patient responses. Spearman’s rank correlation is 0.7, rejecting
the null hypothesis of no association (P  0.02).
The susceptibility to AmB was also measured using a stan-
dard inoculum of 500 CFU/ml (Fig. 2A). The concentration-
response curves for all isolates were similar. At an AmB con-
centration of 1.5 mg/liter, the responses for all isolates were
less than 5 CFU. There was no association between in vitro
response and patient response (Spearman’s rank correlation,
0.08 [P  0.77]) (Fig. 2B).
The MICs obtained from the CLSI microdilution method
are shown in Fig. 2C. The AmB MIC was 0.125 mg/liter for one
isolate and 0.25 mg/liter for the others. This narrow range
limits the use of MICs to predict patient response.
Discussion. The goal of in vitro susceptibility testing is to
predict patient response. We have previously demonstrated
that the baseline severity of meningitis has a strong association
with patient response (2, 12). It seems reasonable that the
response of an individual patient could be affected by both the
baseline fungal burden and the susceptibility of the patient’s
isolate. When susceptibility is measured using a standard in-
FIG. 1. (A) Loess fit of the individual AmB concentration-response curve for each isolate using an in vitro inoculum corresponding to the
baseline CFU per milliliter of CSF for each subject. A filled diamond shows the in vitro response matching the observed patient response at day
14, and the vertical line is drawn at 1.5 mg/liter of AmB, the estimated equivalent concentration. (B) Association between patient quantitative
response at day 14 (vertical axis) and the in vitro responses to AmB at 1.5 mg/liter using patient-specific inocula (Spearman’s rank correlation 
0.7 [P  0.02]).
FIG. 2. (A) Loess fit of the individual AmB concentration-response curve for each isolate using the standard inoculum (500 CFU/ml). The
vertical line is drawn at 1.0 mg/liter of AmB, the concentration with the greatest range in the observed in vitro response. (B) Association between
patient quantitative response at day 14 (vertical axis) and the in vitro responses to AmB at 1.0 mg/liter using the standard inocula (Spearman’s rank
correlation  0.08 [P  0.77]). (C) AmB MICs at 48 h.
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oculum, our results show no association with patient response.
Thus, the challenge for susceptibility testing is to develop an in
vitro model that measures the susceptibility of the individual
strain in the context of the patient’s fungal burden.
In this report, using the patient-specific inoculum, there was
a strong association between in vitro response and patient
response. In contrast, when a standard inoculum was em-
ployed, there was no correlation between in vitro response and
patient response. To our knowledge, this is the first study to
demonstrate an association between AmB susceptibility and
treatment response for patients with cryptococcal meningitis.
These results need to be confirmed in a prospective clinical
trial, in which isolates are collected and quantitative measures
of baseline fungal burden and response are recorded.
Our method for measuring susceptibility requires an esti-
mate of the number of CFU per milliliter in the pretreatment
CSF. In most clinical environments, this is not obtained. How-
ever, these counts can be obtained easily even in modestly
equipped laboratories (see the supplemental material). How-
ever, our current methods are labor intensive. The association
we demonstrate is based on the in vitro response at a single
concentration of AmB (1.5 mg/liter). With additional isolates
and clinical data, it may be possible to simplify the procedures
to employ fewer concentrations.
The quantitative measure of in vitro susceptibility that we
describe, if confirmed, could predict patient response to treat-
ment with AmB alone in AIDS-associated cryptococcal men-
ingitis. This will greatly facilitate decisions regarding treat-
ment. For example, if the susceptibility for a patient indicates
that a large number of viable organisms will remain after 14
days of AmB treatment alone, it may be prudent to combine
AmB with another agent or to increase the duration of therapy
(7, 13).
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